Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Vollenweider F

90 indexed publications match this author name.

ORCID
0000-0001-9053-6164
OpenAlex
https://openalex.org/A5086283052

Author watchlist

Create a confirmed email alert for new publications matching this author.

Publication history

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorderTranslational Psychiatry · 2026-05-26An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applicationsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-03-01Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativitybioRxiv · 2025-11-07Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigmUniversität Zürich, ZORA · 2025-11-05Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use DisorderbioRxiv · 2025-07-18Psilocybin increases emotional empathy in patients with major depression.Molecular psychiatry · 2025-06-01595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCTBiological Psychiatry · 2025-04-09Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trialUniversität Zürich, ZORA · 2025-04-01A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativityResearch Square · 2024-09-26Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.Biological psychiatry · 2024-07-01The influence of psilocybin on subconscious and conscious emotional learning.iScience · 2024-06-21Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01In vitro and in vivo metabolism of psilocybin’s active metabolite psilocinFrontiers in Pharmacology · 2024-04-29Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-04-23Fallbeispiele zur Therapie der rezidivierenden Depression mit PsilocybinNervenheilkunde · 2024-04-01Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-03-26Associations between behavioral and neuronal changes in self-referential processing following a single, moderate dose of psilocybin in depressed patientsNeuroscience Applied · 2024-01-01Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.Scientific reports · 2023-10-14TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.iScience · 2023-05-19Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.EClinicalMedicine · 2023-02-01Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.EClinicalMedicine · 2023-02-01Neural mechanisms of psychedelic visual imagerymedRxiv · 2022-09-09Effective connectivity of emotion and cognition under psilocybinmedRxiv · 2022-09-09Effects of psilocybin in relative and global cerebral blood flow and behavioural correlatesNeuroscience Applied · 2022-01-01Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorderNeuroscience Applied · 2022-01-01Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.Cerebral cortex (New York, N.Y.: 1991) · 2021-11-23P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.Human brain mapping · 2020-12-01Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.Biological psychiatry · 2020-07-15Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.Biomedicines · 2020-02-18Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.Scientific reports · 2019-10-24Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in micebioRxiv · 2019-09-01Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.NeuroImage · 2019-08-01Effects of psilocybin on functional connectivity measured with fNIRS: Insights from a single-subject pilot studyMatters · 2019-01-01Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2018-06-01Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.Current topics in behavioral neurosciences · 2018-01-01Phenomenology, Structure, and Dynamic of Psychedelic States.Current topics in behavioral neurosciences · 2018-01-01Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.NeuroImage · 2017-10-01Effect of Psilocybin on Empathy and Moral Decision-Making.The international journal of neuropsychopharmacology · 2017-09-01LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.Frontiers in pharmacology · 2017-01-01Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination taskEuropean Neuropsychopharmacology · 2016-10-01Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.Proceedings of the National Academy of Sciences of the United States of America · 2016-05-03Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2016-04-01The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.Biological psychiatry · 2015-10-15P.1.i.005 The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteersEuropean Neuropsychopharmacology · 2015-09-01The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-makingEuropean Psychiatry · 2015-03-01Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli - a pharmacological fMRI studyEuropean Neuropsychopharmacology · 2014-09-25Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2013-06-19Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual HallucinationsOpen MIND · 2013-01-01The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.Psychopharmacology · 2013-01-01Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-02-01Prediction of psilocybin response in healthy volunteers.PloS one · 2012-01-01Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.Journal of psychopharmacology (Oxford, England) · 2011-11-01The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.Biological psychiatry · 2011-03-01The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.Nature reviews. Neuroscience · 2010-09-01Psychometric evaluation of the altered states of consciousness rating scale (OAV).PloS one · 2010-08-31Psilocybin slows binocular rivalry switching through serotonin modulationJournal of Vision · 2010-03-19Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptorsJournal of Vision · 2010-03-17GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine · 2009-04-01Serotonin research: contributions to understanding psychoses.Trends in pharmacological sciences · 2008-09-01Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humansInternational Journal of Psychophysiology · 2008-07-17Effects of varied doses of psilocybin on time interval reproduction in human subjects.Neuroscience letters · 2008-04-11Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.Psychopharmacology · 2007-12-01The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2007-09-01Effects of psilocybin on time perception and temporal control of behaviour in humans.Queensland's institutional digital repository (The University of Queensland) · 2006-05-18Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.Journal of cognitive neuroscience · 2005-10-01Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2005-06-01Psilocybin impairs high-level but not low-level motion perception.Neuroreport · 2004-08-26Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.Psychopharmacology · 2004-03-01The Effects of he Hallucinogenic Serotonin 1A/2A Agonist, Psilocybin, on Binocular Rivalry and Visual Contrast Detection ThresholdsQueensland's institutional digital repository (The University of Queensland) · 2003-12-31P.6.057 Effects of 2A receptor challenge by psilocybin on cognitive performance and neuroendocrine measures in healthy humans: A serotonin model of psychosisEuropean Neuropsychopharmacology · 2003-10-01[Hallucinogens, amphetamines and entactogens].Therapeutische Umschau. Revue therapeutique · 2003-06-01A double-blind, placebo controlled study of the effect of the hallucinogenic 5-HT1A&2A agonist psilocybin on binocular rivalry rate and rhythmicitySocial Neuroscience · 2003-01-01Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2003-01-01Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in manJournal of Pharmaceutical and Biomedical Analysis · 2002-09-01Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.Biological psychiatry · 2002-03-01Brain mechanisms of hallucinogens and entactogens.Dialogues in clinical neuroscience · 2001-12-01A systems model of altered consciousness: integrating natural and drug-induced psychoses.Brain research bulletin · 2001-11-15177. NMDA and 5-HT2A receptor dysfunction in working memory deficits in schizophreniaBiological Psychiatry · 2000-03-315-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 1999-05-01Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport · 1998-12-01Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.Pharmacopsychiatry · 1998-07-0111C-radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formationJournal of Labelled Compounds and Radiopharmaceuticals · 1998-07-01Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in manPharmaceutica Acta Helvetiae · 1997-06-01Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 1997-05-01

Author directory

Robin Carhart-Harris176 publicationsDavid Nutt121 publicationsDavid Erritzøe84 publicationsFranz X. Vollenweider84 publicationsRoland R. Griffiths84 publicationsMatthew W. Johnson69 publicationsKatrin H. Preller64 publicationsFrederick S. Barrett60 publicationsGitte M. Knudsen57 publicationsLeor Roseman55 publicationsJames Rucker48 publicationsAlbert Garcia-Romeu46 publicationsTomáš Páleníček44 publicationsPatrick M. Fisher43 publicationsSandeep M. Nayak43 publicationsKim P. C. Kuypers42 publicationsDea Siggaard Stenbæk41 publicationsJoshua D. Rosenblat41 publicationsNatasha L. Mason39 publicationsPeter S. Hendricks37 publicationsAlan K. Davis35 publicationsChristopher Timmermann33 publicationsDavid Bryce Yaden33 publicationsMatthias E. Liechti33 publicationsMuhammad Ishrat Husain33 publicationsBrice Ozenne32 publicationsJohns Hopkins University31 publicationsGuy M. Goodwin30 publicationsHannes Kettner30 publicationsJohannes G. Ramaekers30 publicationsStephen Ross30 publicationsMichael P. Bogenschutz29 publicationsRoger S. McIntyre29 publicationsDirk Hoffmeister28 publicationsErich Seifritz27 publicationsRobert B. Kargbo27 publicationsRichard J. Zeifman26 publicationsBrian Anderson25 publicationsMartin Korsbak Madsen25 publicationsAllan H. Young24 publicationsCharles D. Nichols24 publicationsDrummond E-Wen McCulloch24 publicationsGabrielle Agin-Liebes24 publicationsJavier González-Maeso24 publicationsMartin Kuchař24 publicationsMorten L. Kringelbach24 publicationsNathan D. Sepeda24 publicationsNatalie Gukasyan23 publicationsPaul Liknaitzky23 publicationsXiaohui Wang23 publicationsFriederike Holze22 publicationsGustavo Deco22 publicationsScott Aaronson22 publicationsBrian S. Barnett21 publicationsBruna Giribaldi21 publicationsOlivia Carter21 publicationsOtto Simonsson21 publicationsRafael G. dos Santos21 publicationsAdam L. Halberstadt20 publicationsAlex Kwan20 publicationsManoj Doss20 publicationsMichael Kometer20 publicationsBenjamin Kelmendi19 publicationsBernard Lerer19 publicationsJacob S. Aday19 publicationsJaime E. C. Hallak19 publicationsJiřı́ Horáček19 publicationsMatthew B. Wall19 publicationsRoland A. Fischer19 publicationsRotem Petranker19 publicationsCharles L. Raison18 publicationsDavid E. Nichols18 publicationsEnzo Tagliazucchi18 publicationsMendel Kaelen18 publicationsRobert A. Schoevers18 publicationsAlexander M. Sherwood17 publicationsAmanda Feilding17 publicationsClaire J. Foldi17 publicationsDavid J. Hellerstein17 publicationsFelix Müller17 publicationsFernando Rosas17 publicationsFilip Tylš17 publicationsJeffrey Guss17 publicationsManish Agrawal17 publicationsMilan Scheidegger17 publicationsTomislav Majić17 publicationsWilliam A. Richards17 publicationsChristopher S. Stauffer16 publicationsKevin F. Boehnke16 publicationsMalievskaia E16 publicationsNadav Liam Modlin16 publicationsSophia Armand16 publicationsYale University16 publicationsCharles S. Grob15 publicationsEmmanuelle A. D. Schindler15 publicationsFelix Hasler15 publicationsGeyer MA15 publicationsJason B. Luoma15 publicationsKelly JR15 publicationsLea J. Mertens15 publicationsLindsey Marwood15 publicationsPablo Mallaroni15 publicationsSuresh Muthukumaraswamy15 publicationsTzuri Lifschytz15 publicationsUniversity Hospital15 publicationsAnna M. Becker14 publicationsBoadie W. Dunlop14 publicationsBrandon Weiss14 publicationsFederico Seragnoli14 publicationsGerhard Gründer14 publicationsHenrik Jungaberle14 publicationsJanis Fricke14 publicationsJeng-Yu Tsai14 publicationsJochen Gartz14 publicationsJoshua S. Siegel14 publicationsMeg J Spriggs14 publicationsMika Turkia14 publicationsNathalie M. Rieser14 publicationsRodrigo B. Mansur14 publicationsSusan L. Rossell14 publications